Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

Esperion Therapeutics (ESPR) Misses Q3 EPS by 57c

November 6, 2019 5:28 PM EST

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.52), $0.57 worse than the analyst estimate of ($1.95). Revenue for the quarter came in at $981 thousand versus the consensus estimate of $900 thousand.

The Esperion Lipid Management Team continues to lay a strong and durable foundation for what we... More